Imagine a world where a multiple myeloma diagnosis no longer meant facing a life expectancy measured in just months, but in years—many years, filled with significant milestones.
Key Takeaways
- Median overall survival for multiple myeloma patients diagnosed between 2013-2019 is 72.3 months according to SEER data
- 5-year relative survival rate for multiple myeloma is 59.8% for patients diagnosed 2014-2020 per American Cancer Society
- Median OS of 124 months for transplant-eligible patients in the era of novel agents from IMF data
- Median PFS of 18.1 months with bortezomib-melphalan-prednisone (VMP) in VISTA trial for NDMM non-transplant
- PFS at 3 years is 56% with daratumumab-VMP in ALCYONE trial
- Median PFS of 20.6 months with carfilzomib-lenalidomide-dexamethasone (KRd) in ASPIRE trial for RRMM
- Median ISS stage I survival is 61.1 months vs stage III 29.9 months per original ISS
- R-ISS stage I 5-year OS 82% vs stage III 40% in 2015 validation cohort
- Median OS for ISS stage II is 44.2 months in novel agent era
- Median OS 108 months for patients <65 years with ASCT in IFM trials
- 5-year OS 42% for patients aged 75+ vs 68% <65 per SEER 2015-2019
- Median OS 34 months for high-risk cytogenetics (del17p, t4;14, t14;16)
- Median OS 82 months with VRd + ASCT in transplant-eligible <70 years
- 4-year OS 71% with daratumumab-VMP quadruplet in elderly NDMM ALCYONE
- Median PFS 31 months KRd continuous vs 20 months Rd in transplant-ineligible
Modern treatments have greatly improved multiple myeloma survival rates over time.
Overall Survival Statistics
1Median overall survival for multiple myeloma patients diagnosed between 2013-2019 is 72.3 months according to SEER data
Verified25-year relative survival rate for multiple myeloma is 59.8% for patients diagnosed 2014-2020 per American Cancer Society
Verified3Median OS of 124 months for transplant-eligible patients in the era of novel agents from IMF data
Verified410-year OS rate of 44% for standard-risk myeloma patients post-ASCT
Directional5Median OS improved from 29.4 months (1990s) to 62.1 months (2010s) per Mayo Clinic study
Single source6OS at 3 years is 82% for newly diagnosed myeloma with VRd induction
Verified7Median OS of 82.8 months for patients with IgG myeloma subtype
Verified85-year OS rate of 57.2% for localized myeloma vs 51.1% distant stage per SEER 2015-2019
Verified9Median OS of 5.3 years for African American patients vs 4.8 years for whites
Directional10OS probability at 5 years is 55% with bortezomib-based regimens in elderly
Single source11Median OS of 136 months for patients achieving CR post-induction
Verified127-year OS rate of 50% for transplant-ineligible NDMM with Rd continuous
Verified13Median OS of 43 months for relapsed/refractory myeloma post-lenalidomide
Verified143-year OS of 70% in high-dose melphalan + ASCT arm of IFM 2009 trial
Directional15OS at 8 years is 41% for patients with del(17p) despite modern therapy
Single source16Median OS of 96 months for R-ISS stage I patients diagnosed 2011-2018
Verified175-year OS improved to 61% from 34% between 2000-2019 per Swedish registry
Verified18Median OS of 75 months for patients over 75 years with Dara-VMP
Verified1910-year OS rate of 37% for NDMM with autologous stem cell transplant
Directional20OS hazard ratio 0.72 for quadruplet vs triplet therapy in ALCYONE trial
Single source21Median OS of 53 months for extramedullary disease at diagnosis
Verified224-year OS of 68% with isatuximab + Pd in RRMM per ICARIA-MM
Verified23Median OS of 112 months for hyperdiploid myeloma patients
Verified245-year OS rate of 64% for females vs 55% males per SEER 2016-2020
Directional25OS at 2 years is 91% with VRd in transplant-eligible NDMM from SWOG S0777
Single source26Median OS of 47 months for t(4;14) positive patients
Verified276-year OS of 52% post-maintenance lenalidomide in CALGB 100104
Verified28Median OS of 125 months for patients <65 years with standard risk
Verified293-year OS rate of 78% with Dara-VRd in GRIFFIN trial
Directional30OS probability at 10 years is 28% for R-ISS stage III
Single sourceOverall Survival Statistics Interpretation
We are witnessing a story of remarkable scientific progress where a once nearly uniformly fatal diagnosis is becoming a chronic disease for many, yet the tale is punctuated by stark inequalities where a patient’s survival is still heavily dictated by their age, race, genetic risk, and, crucially, their timely access to the latest quadruplet and monoclonal antibody therapies.
Progression-Free Survival Statistics
1Median PFS of 18.1 months with bortezomib-melphalan-prednisone (VMP) in VISTA trial for NDMM non-transplant
Verified2PFS at 3 years is 56% with daratumumab-VMP in ALCYONE trial
Verified3Median PFS of 20.6 months with carfilzomib-lenalidomide-dexamethasone (KRd) in ASPIRE trial for RRMM
Verified412-month PFS rate of 86.9% with daratumumab-VRd in GRIFFIN trial for transplant-eligible NDMM
Directional5Median PFS of 30.4 months with VRd induction followed by ASCT and lenalidomide maintenance in SWOG S0777
Single source6PFS hazard ratio 0.56 with isatuximab-pomalidomide-dex (Isa-Pd) vs Pd in ICARIA-MM
Verified7Median PFS of 11.9 months with lenalidomide-dexamethasone (Rd) in MM-009/010 trials for RRMM
Verified818-month PFS of 68% with quadruplet Dara-KRd in PERSEUS trial NDMM
Verified9Median PFS of 16.8 months with pomalidomide-dex in IFM 2010-03 trial RRMM
Directional10PFS at 24 months is 82.9% with D-VRd vs 74.3% VRd in PERSEUS
Single source11Median PFS of 43 months with continuous Rd in FIRST trial transplant-ineligible NDMM
Verified126-month PFS rate of 71.6% with selinexor + bortezomib-dex in BOSTON trial
Verified13Median PFS of 22.4 months with elotuzumab-lenalidomide-dex (Elo-Rd) in ELOQUENT-2
Verified14PFS at 1 year is 88% post-ASCT with bortezomib maintenance in HOVON-65/GMMG-HD4
Directional15Median PFS of 28.6 months with daratumumab-Rd in MAIA trial elderly NDMM
Single source1636-month PFS of 57.9% with teclistamab in CARTITUDE-1 for RRMM
Verified17Median PFS of 13.3 months with Pd in ICARIA-MM control arm
Verified18PFS hazard ratio 0.42 with cilta-cel vs standard in CARTITUDE-4 NDMM
Verified19Median PFS of 34.2 months with KRd + ASCT in FORTE trial
Directional2012-month PFS of 92.2% with D-VMP in ALCYONE
Single source21Median PFS of 19.2 months with ixazomib-Rd in TOURMALINE MM1 RRMM
Verified22PFS at 18 months is 51% with RVd in transplant-ineligible from MAIA-like
Verified23Median PFS of 67.9 months with Dara-VRd induction in GRIFFIN post-ASCT
Verified2424-week PFS rate of 89.7% with belantamab mafodotin in DREAMM-2
Directional25Median PFS of 7.5 months with Vd in POLLUX control for RRMM
Single source2630-month PFS of 47.5% with Elo-Rd in ELOQUENT-2
Verified27Median PFS of 25.7 months with D-Vd in CASTOR trial RRMM
VerifiedProgression-Free Survival Statistics Interpretation
While these numbers reveal a clear and steady march toward turning myeloma into a chronic condition, they also serve as a humbling reminder that progress is measured not just in months gained, but in the relentless pursuit of turning today’s remarkable response rates into tomorrow’s durable cures.
Survival by Patient Factors
1Median OS 108 months for patients <65 years with ASCT in IFM trials
Verified25-year OS 42% for patients aged 75+ vs 68% <65 per SEER 2015-2019
Verified3Median OS 34 months for high-risk cytogenetics (del17p, t4;14, t14;16)
Verified4OS HR 1.45 for males vs females in large US cohort
Directional5Median survival 28 months with renal failure (CrCl<30) at diagnosis
Single source63-year OS 85% for standard-risk vs 60% high-risk post-ASCT
Verified7Median OS 62 months for African Americans vs 55 months Caucasians adjusted
Verified8Survival reduced by 20 months with extramedullary plasmacytomas
Verified910-year OS 50% for patients with hyperdiploidy vs 30% gain(1q)
Directional10Median OS 48 months for obese patients (BMI>30) NDMM
Single source11PFS shorter by 12 months in frail elderly per IMWG frailty index
Verified12OS 72 months median for IgA vs 68 months IgG subtype
Verified135-year OS 55% with anemia (Hb<10g/dL) vs 65% without
Verified14Median survival 40 months with high LDH (>UNL) at diagnosis
Directional15OS HR 1.8 for smokers in myeloma cohort studies
Single source167-year OS 45% for diabetic comorbid patients vs 58% non-diabetic
Verified17Median PFS 22 months del(17p) vs 38 months standard risk
Verified18Survival 15% lower in rural vs urban residence per registry data
Verified19Median OS 55 months with bone disease (≥3 lesions) vs 75 without
Directional204-year OS 70% ECOG 0-1 vs 50% ECOG 2+ performance status
Single source21Median survival 36 months gain(1q) high-level amplification
Verified22OS improved 18 months with insurance coverage in US disparities study
Verified235-year OS 60% beta-2 microglobulin <3.5 mg/L vs 40% >5.5
Verified24Median PFS 15 months t(4;14) despite intensified therapy
Directional25Survival HR 2.1 for age >80 vs <60 in transplant-ineligible
Single source263-year OS 78% albumin >3.5 g/dL vs 62% low albumin ISS factor
VerifiedSurvival by Patient Factors Interpretation
This stark collection of numbers paints a clear, human portrait: survival in myeloma is not a single statistic but a complex equation where the final sum is profoundly shaped by the biology we bring, the bodies we inhabit, the resources we can access, and the sheer luck of our genetic draw.
Survival by Staging Systems
1Median ISS stage I survival is 61.1 months vs stage III 29.9 months per original ISS
Verified2R-ISS stage I 5-year OS 82% vs stage III 40% in 2015 validation cohort
Verified3Median OS for ISS stage II is 44.2 months in novel agent era
Verified4R-ISS stage II median PFS 36 months vs stage I 52 months in CASSIOPEIA
Directional53-year OS 91% for R-ISS I vs 56% for R-ISS III in transplant-eligible
Single source6Median survival for Durie-Salmon stage IIIA is 48 months vs IIIB 28 months
Verified7ISS stage I median OS 93 months in era of Rev/Dex + ASCT
Verified8R-ISS high-risk (III) median OS 35.9 months post-2015 diagnosis
Verified9SLiM CRAB criteria high tumor burden median OS 42 months
Directional10Median PFS for R-ISS II 28 months with VRD-based therapy
Single source11ISS stage III 5-year survival 28% vs 65% stage I per SEER linked data
Verified12Revised ISS stage I OS at 5 years 81.9% in European cohort
Verified13Median OS 52 months for stage II DS staging with renal impairment
Verified14R-ISS III median survival 43 months in high LDH subgroup
Directional15ISS I/II combined median PFS 32 months post-ASCT maintenance
Single source1610-year OS for R-ISS I 60% vs 15% R-ISS III in long-term follow-up
Verified17Median OS 67 months for low-risk by FISH vs 36 high-risk ISS adjusted
Verified18Stage IIIB DS median survival 24 months in pre-novel era update
Verified19R-ISS stage II 3-year PFS 65% with quadruplet induction
Directional20ISS stage I survival rate 70% at 7 years with bortezomib induction
Single source21Median OS R-ISS I 125 months vs III 36 months in GMMG cohort
Verified22PFS for high cytogenetic risk within ISS II 18 months median
Verified235-year OS 75% R-ISS I elderly NDMM with D-VMP
Verified24Median survival stage I DS 72 months in modern registries
Directional25R-ISS adjusted OS HR 2.2 for stage III vs I in meta-analysis
Single source26Median PFS 45 months ISS I post KRd ASCT in FORTE
VerifiedSurvival by Staging Systems Interpretation
This stark statistical chasm between stages, where a myeloma diagnosis can feel like either a manageable marathon or a desperate sprint, underscores the brutal truth that early detection and accurate risk stratification are not just medical jargon—they are the difference between measuring survival in years versus decades.
Survival by Treatment Modalities
1Median OS 82 months with VRd + ASCT in transplant-eligible <70 years
Verified24-year OS 71% with daratumumab-VMP quadruplet in elderly NDMM ALCYONE
Verified3Median PFS 31 months KRd continuous vs 20 months Rd in transplant-ineligible
Verified436-month OS 84% Dara-Rd vs 68% Rd in MAIA trial
Directional5Median OS not reached at 5 years with lenalidomide maintenance post-ASCT
Single source6PFS HR 0.48 daratumumab-VRd vs VRd in PERSEUS NDMM
Verified712-month PFS 77% selinexor-Vd vs 34% Vd in BOSTON RRMM
Verified8Median OS 47.6 months teclistamab vs 34.3 months SOC in Majestea-1
Verified95-year PFS 48% bortezomib maintenance post-ASCT HOVON-65
Directional10OS HR 0.53 cilta-cel vs SOC in CARTITUDE-4 high-risk NDMM
Single source11Median PFS 29.6 months Elo-Rd vs 10.9 Rd ELOQUENT-2 RRMM
Verified1230-month OS 79% D-Vd vs 63% Vd CASTOR RRMM
Verified13Median survival doubled with ASCT vs no transplant in 65-70 yo
Verified14PFS 20.6 months carfilzomib-Rd ASPIRE vs 15.6 Rd
Directional1548-month PFS 65.2% Isa-Pd vs 37.2% Pd ICARIA-MM
Single source16Median OS 31.4 months D-Rd vs 19.4 Rd POLLUX RRMM
Verified173-year PFS 57% ixazomib-Rd vs 42% Rd TOURMALINE MM1
Verified18OS benefit 12 months with pomalidomide vs HSCT salvage in RRMM
Verified19Median PFS 18 months VMP vs 24 months Rd FIRST trial comparison
Directional2024-month OS 85% with D-VRd in GRIFFIN post-consolidation
Single sourceSurvival by Treatment Modalities Interpretation
We've reached a point in myeloma care where, if you cleverly pick your weapons and sequence your attacks, you can plausibly plan your life around this disease instead of constantly planning your death from it.